Low-Carbohydrate Diet for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Low-Carbohydrate Diet for Health & Longevity

Created on 09/01/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A well-defined lever with a well-defined price. Where blood sugar, weight or blood fats are out of range, the evidence for benefit is strong and repeatedly demonstrated. Where the starting point is lean and healthy, the upside shrinks to appetite control and blood fats, while cholesterol rises most. What replaces the carbohydrate appears to matter more than the amount removed. (Full Review)

Protocol

The carbohydrate target comes first
100–130 / 50–100 / under 50 g net daily
Three bands: moderate, low and ketogenic; frequently 20–30 g during an induction phase
Baseline biomarkers guide the target
Strictest band for high HbA1c, insulin or triglycerides
A lean starting point with normal blood fats argues for moderate restriction, because the LDL rise is steepest at a low body mass index
Kinetics and dose splitting
Carbohydrate split across two or three meals
Beta-hydroxybutyrate has a plasma half-life of one to two hours, so ketosis is maintained meal to meal, not dosed
Time to effect
Blood glucose
24–72 hours
Blood ketones rise within 2–4 days
Weight loss
Week one
Front-loads with water
Triglycerides
4 weeks
Lipid changes should not be judged before 8–12 weeks

Benefits

Contraindications
  • Fatty acid oxidation disorders, carnitine deficiencies, pyruvate carboxylase deficiency, porphyria
  • Type 1 diabetes without specialist supervision and continuous glucose monitoring
  • Pregnancy and lactation
  • Severe kidney impairment (estimated glomerular filtration rate under 30 mL/min/1.73 m²)
  • Advanced liver failure (Child-Pugh Class C)
  • Active or recent pancreatitis (within 3 months)
  • Current or past restrictive eating disorder
    •
Key Interactions
  • Insulin (all types)
  • Sulfonylureas (glipizide, glyburide, glimepiride)
  • SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin)
  • Antihypertensives and diuretics (lisinopril, amlodipine, hydrochlorothiazide, furosemide)
  • Warfarin
  • Lithium
  • Over-the-counter anti-inflammatory painkillers (ibuprofen, naproxen, high-dose aspirin)
  • Supplement interactions (berberine, chromium, alpha-lipoic acid)
  • Additive electrolyte and blood-pressure supplements (magnesium, potassium, beetroot or nitrate products)
  • Exogenous ketone salts and medium-chain triglyceride oil
  • Other dietary interventions (prolonged fasting, heavy endurance training)
    •

Risk & Side Effects

  • High: LDL cholesterol and apolipoprotein B elevation; impaired endurance and high-intensity exercise performance
  • Medium: Induction symptoms and gastrointestinal disturbance; kidney stones; suppressed bone formation markers; diabetic ketoacidosis when combined with SGLT2 inhibitors; hyperuricemia and gout risk on animal-based patterns; reduced testosterone on high-protein variants
  • Low: Increased all-cause and cancer mortality; lean mass loss on non-energy-restricted ketogenic variants; reduced fibre intake and microbiome change
  • Speculative: Accelerated cellular senescence; reduced thyroid hormone conversion

Monitoring

Marker Target Why
HbA1c 4.8–5.4% Tracks the primary metabolic target
Fasting insulin 2–5 µIU/mL The upstream variable the diet acts on
Apolipoprotein B Under 80 mg/dL, under 60 with established plaque Counts atherogenic particles; the key safety marker
LDL cholesterol Under 100 mg/dL, individualised Detects the large-magnitude responder phenotype
Triglycerides Under 80 mg/dL The most responsive benefit marker
HDL cholesterol Above 50 mg/dL (men), above 60 (women) Rises with carbohydrate restriction; part of the responder phenotype
Beta-hydroxybutyrate 0.5–3.0 mmol/L if ketosis is the goal Confirms the intended metabolic state
Uric acid Under 5.5 mg/dL Flags stone and gout risk on animal-based patterns
Comprehensive metabolic panel with eGFR eGFR above 90 mL/min/1.73 m² Kidney and liver safety monitoring
Magnesium (red blood cell) 5.0–6.5 mg/dL Explains cramps, palpitations and poor sleep during induction
Free triiodothyronine with thyroid-stimulating hormone Free T3 3.0–4.2 pg/mL; TSH 0.5–2.0 mIU/L Detects the downward thyroid shift on strict restriction
Body composition (DEXA or bioimpedance) No established target; track change from the individual's own baseline, preserving or increasing lean mass Separates useful fat loss from muscle loss
Vitamin D, 25-hydroxy 40–60 ng/mL Interacts with bone-turnover concerns

Cadence: Blood glucose and ketones daily for two weeks; electrolytes and blood pressure at 2–4 weeks; a full repeat panel at 3 months, again at 6 months, then every 6–12 months once values are stable. Lipids warrant a recheck after any large change in body weight.

Qualitative Assessment

  • Energy through the afternoon, which typically improves by week 3–4 once adaptation is complete
  • Sleep onset and night waking, which often worsen briefly during induction
  • Cognitive clarity and mental stamina during demanding work
  • Hunger between meals, and whether food thoughts have quietened
  • Exercise capacity at high intensity, which is the first thing to degrade
  • Bowel regularity, an early proxy for fibre adequacy
  • Cold intolerance, dizziness on standing, and cramps, all of which point to electrolytes or an excessively low target
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.